Influence of growth hormone on a new marker of cartilage metabolism (Chondrex)

G. Radetti, M. Bozzola, V. Braga, C. Paganini, C. Moretti, S. Adami

Research output: Contribution to journalArticle

Abstract

The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age 8.8 ± 2.7 years, height -2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months of treatment with rhGH, a significant increase of height velocity SDS (from -2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47 to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker of bone responsiveness to GH in the growing child.

Original languageEnglish
Pages (from-to)45-46
Number of pages2
JournalCalcified Tissue International
Volume67
Issue number1
Publication statusPublished - 2000

Fingerprint

Growth Hormone
Cartilage
Bone and Bones
Alkaline Phosphatase
Serum
Pituitary Dwarfism
Chondrocytes
Biomarkers
human CHI3L1 protein
Therapeutics
Proteins

Keywords

  • Chondrex
  • Growth
  • Growth hormone
  • XKL-40

ASJC Scopus subject areas

  • Endocrinology

Cite this

Radetti, G., Bozzola, M., Braga, V., Paganini, C., Moretti, C., & Adami, S. (2000). Influence of growth hormone on a new marker of cartilage metabolism (Chondrex). Calcified Tissue International, 67(1), 45-46.

Influence of growth hormone on a new marker of cartilage metabolism (Chondrex). / Radetti, G.; Bozzola, M.; Braga, V.; Paganini, C.; Moretti, C.; Adami, S.

In: Calcified Tissue International, Vol. 67, No. 1, 2000, p. 45-46.

Research output: Contribution to journalArticle

Radetti, G, Bozzola, M, Braga, V, Paganini, C, Moretti, C & Adami, S 2000, 'Influence of growth hormone on a new marker of cartilage metabolism (Chondrex)', Calcified Tissue International, vol. 67, no. 1, pp. 45-46.
Radetti, G. ; Bozzola, M. ; Braga, V. ; Paganini, C. ; Moretti, C. ; Adami, S. / Influence of growth hormone on a new marker of cartilage metabolism (Chondrex). In: Calcified Tissue International. 2000 ; Vol. 67, No. 1. pp. 45-46.
@article{7e46977babc54fc2974659c7e63cfd9a,
title = "Influence of growth hormone on a new marker of cartilage metabolism (Chondrex)",
abstract = "The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age 8.8 ± 2.7 years, height -2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months of treatment with rhGH, a significant increase of height velocity SDS (from -2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47 to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker of bone responsiveness to GH in the growing child.",
keywords = "Chondrex, Growth, Growth hormone, XKL-40",
author = "G. Radetti and M. Bozzola and V. Braga and C. Paganini and C. Moretti and S. Adami",
year = "2000",
language = "English",
volume = "67",
pages = "45--46",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Influence of growth hormone on a new marker of cartilage metabolism (Chondrex)

AU - Radetti, G.

AU - Bozzola, M.

AU - Braga, V.

AU - Paganini, C.

AU - Moretti, C.

AU - Adami, S.

PY - 2000

Y1 - 2000

N2 - The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age 8.8 ± 2.7 years, height -2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months of treatment with rhGH, a significant increase of height velocity SDS (from -2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47 to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker of bone responsiveness to GH in the growing child.

AB - The aim of this study was to evaluate the usefulness of a major secretory protein of human chondrocytes (chondrex) as a potential serum marker of bone responsiveness to growth hormone (GH). The study included 18 children (10 F, 8 M), aged 10.9 ± 2.3 years, bone age 8.8 ± 2.7 years, height -2.3 ± 0.22 SDS, affected by isolated idiopathic GH deficiency (GHD). Serum samples for evaluation of chondrex, total, and bone alkaline phosphatase were taken before and 3 and 6 months following treatment with rhGH. The basal serum level of chondrex did not differ between patients (37 ± 22 ng/ml) and controls (33 ± 9.8 ng/ml). Following 6 months of treatment with rhGH, a significant increase of height velocity SDS (from -2.8 ± 0.5 to 1.3 ± 0.7), total (from 195 ± 47 to 264 ± 79 U/liter) and bone alkaline phosphatase (from 81 ± 21 to 108 ± 30 U/liter) was observed, while chondrex serum level remained unchanged (from 37 ± 22 to 36 ± 29 ng/ml). It was concluded that chondrex cannot be considered a reliable marker of bone responsiveness to GH in the growing child.

KW - Chondrex

KW - Growth

KW - Growth hormone

KW - XKL-40

UR - http://www.scopus.com/inward/record.url?scp=0033941291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033941291&partnerID=8YFLogxK

M3 - Article

C2 - 10908412

AN - SCOPUS:0033941291

VL - 67

SP - 45

EP - 46

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 1

ER -